-
公开(公告)号：US20240140937A1
公开(公告)日：2024-05-02
申请号：US18520638
申请日：2023-11-28
Applicant: Pfizer Inc.
Inventor： Markus Boehm , Shawn Cabral , Matthew S. Dowling , Kentaro Futatsugi , Kim Huard , Esther Cheng Yin Lee , Allyn T. Londregan , Jana Polivkova , David A. Price , Qifang Li
IPC: C07D405/14 , A61K31/506 , A61K45/06 , C07D401/14 , C07D409/14
CPC classification number: C07D405/14 , A61K31/506 , A61K45/06 , C07D401/14 , C07D409/14 , A61P3/06
Abstract: Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.
-
公开(公告)号：US20240366598A1
公开(公告)日：2024-11-07
申请号：US18634154
申请日：2024-04-12
Applicant: Pfizer Inc.
Inventor： Kevin James Filipski , Matthew Forrest Sammons , Samuel Michael Levi , Yang Wang , Advaita Panchagnula , Yanfei Guan , Matthew Richard Reese , Luis Angel Martinez Alsina , Steven Victor O'Neil , Lei Zhang , Qifang Li , Ethan Lawrence Fisher , Danica Antonia Rankic
IPC: A61K31/506 , A61K31/403 , A61K31/4439 , A61K31/444 , A61P3/04 , C07D207/16 , C07D209/52 , C07D401/12 , C07D401/14 , C07D403/12
Abstract: Described herein are compounds of Formula I: and their pharmaceutically acceptable salts, wherein R1, R2, R3, L1, T1, T2, T3, T4, t1, and t2 are defined herein; their use as GIPR antagonists; pharmaceutical compositions containing such compounds and salts; and the use of such compounds and salts to treat or prevent, for example, obesity, weight gain, and/or T2DM.
-
公开(公告)号：US10071992B2
公开(公告)日：2018-09-11
申请号：US15674914
申请日：2017-08-11
Applicant: Pfizer Inc.
Inventor： Markus Boehm , Shawn Cabral , Matthew S. Dowling , Kentaro Futatsugi , Kim Huard , Esther Cheng Yin Lee , Allyn T. Londregan , Jana Polivkova , David A. Price , Qifang Li
IPC: C07D401/00 , C07D253/08 , C07D401/04 , A61K9/14 , C07D405/14 , A61K31/506 , A61K45/06 , C07D409/14 , C07D401/14
Abstract: Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.
-
公开(公告)号：US20180051012A1
公开(公告)日：2018-02-22
申请号：US15674914
申请日：2017-08-11
Applicant: Pfizer Inc.
Inventor： Markus Boehm , Shawn Cabral , Matthew S. Dowling , Kentaro Futatsugi , Kim Huard , Esther Cheng Yin Lee , Allyn T. Londregan , Jana Polivkova , David A. Price , Qifang Li
IPC: C07D405/14 , A61K31/506 , A61K45/06 , C07D409/14
CPC classification number: C07D405/14 , A61K31/506 , A61K45/06 , C07B2200/13 , C07D401/14 , C07D409/14
Abstract: Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.
-
Patent Agency Ranking
公开(公告)号：US11034678B2
公开(公告)日：2021-06-15
申请号：US16793441
申请日：2020-02-18
Applicant: Pfizer Inc.
Inventor： Markus Boehm , Shawn Cabral , Matthew S. Dowling , Kentaro Futatsugi , Kim Huard , Esther Cheng Yin Lee , Allyn T. Londregan , Jana Polivkova , David A. Price , Qifang Li
IPC: C07D401/04 , C07D405/14 , C07D401/14 , A61K31/506 , A61K45/06 , C07D409/14
Abstract: Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.
-
公开(公告)号：US20180258081A1
公开(公告)日：2018-09-13
申请号：US15977238
申请日：2018-05-11
Applicant: Pfizer Inc.
Inventor： Markus Boehm , Shawn Cabral , Matthew S. Dowling , Kentaro Futatsugi , Kim Huard , Esther Cheng Yin Lee , Allyn T. Londregan , Jana Polivkova , David A. Price , Qifang Li
IPC: C07D405/14 , C07D401/14 , C07D409/14 , A61K31/506 , A61K45/06
Abstract: Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.
-
公开(公告)号：US11866425B2
公开(公告)日：2024-01-09
申请号：US17345064
申请日：2021-06-11
Applicant: Pfizer Inc.
Inventor： Markus Boehm , Shawn Cabral , Matthew S. Dowling , Kentaro Futatsugi , Kim Huard , Esther Cheng Yin Lee , Allyn T. Londregan , Jana Polivkova , David A. Price , Qifang Li
IPC: A61K31/505 , A61P3/00 , A61P3/10 , A61P3/06 , C07D405/14 , C07D401/14 , A61K31/506 , A61K45/06 , C07D409/14
CPC classification number: C07D405/14 , A61K31/506 , A61K45/06 , C07D401/14 , C07D409/14 , A61P3/00 , A61P3/06 , A61P3/10 , C07B2200/13
Abstract: Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.
-
公开(公告)号：US20210309646A1
公开(公告)日：2021-10-07
申请号：US17345064
申请日：2021-06-11
Applicant: Pfizer Inc.
Inventor： Markus Boehm , Shawn Cabral , Matthew S. Dowling , Kentaro Futatsugi , Kim Huard , Esther Cheng Yin Lee , Allyn T. Londregan , Jana Polivkova , David A. Price , Qifang Li
IPC: C07D405/14 , C07D401/14 , A61K31/506 , A61K45/06 , C07D409/14
Abstract: Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.
-
公开(公告)号：US20200181127A1
公开(公告)日：2020-06-11
申请号：US16793441
申请日：2020-02-18
Applicant: Pfizer Inc.
Inventor： Markus Boehm , Shawn Cabral , Matthew S. Dowling , Kentaro Futatsugi , Kim Huard , Esther Cheng Yin Lee , Allyn T. Londregan , Jana Polivkova , David A. Price , Qifang Li
IPC: C07D405/14 , C07D409/14 , A61K45/06 , A61K31/506 , C07D401/14
Abstract: Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.013 seconds)
